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thetic valves (OR, 1.61; 95% CI, 1.27-2.04; P< 0.0001). The risk difference decreased 
to 16% during 30 days after the surgery date (OR, 1.18; 95% CI, 1.09-1.28; P< 0.0001). 
There were no differences within 31 to 365 days after the surgery date and within 
the 30 days post-discharge. Risk of operative mortality was 19% higher for mechani-
cal valves than for bioprosthetic valves (OR, 1.21; 95% CI, 1.13-1.30; P< 0.0001). The 
number needed to treat with mechanical valves to observe one additional death 
on the surgery date was 290. Consistent findings were observed in subgroup analy-
ses of patients who underwent concurrent AVR and Coronary Artery Bypass Graft 
(CABG), but not in isolated AVR subgroup. ConClusions: In this cohort analysis 
of Medicare beneficiaries, mechanical aortic valves were associated with a higher 
risk of death on the surgery date and within the 30 days following surgery when 
compared with bioprosthetic aortic valves among patients who underwent concur-
rent AVR and CABG, but not isolated AVR.
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ComParatiVe effeCtiVeness of angiotensin ConVerting enzyme 
inhibitors and angiotensin ii reCePtor bloCkers in heart failure
Sharma M., Johnson M.L., Chen H., Aparasu R.
University of Houston, Houston, TX, USA
objeCtives: The objectives were to determine the comparative effectiveness 
of Angiontensin II receptor blockers (ARB) and Angiotensin converting enzyme 
Inhibitors (ACEI) in patients with heart failure (HF), and to determine comparative 
effectiveness of individual drugs within classes - ACEIs and ARBs. Methods: A 
retrospective national cohort of Veterans Affairs patients with HF from 1997 to 
2002 was employed. Exposure to ARB therapy or ACEI therapy was seen in 2002. 
Mortality as outcome was assessed within one year of follow-up. Multivariate Cox 
proportional hazards regression and propensity scoring techniques were employed 
for data analysis, adjusting for 45 patient risk factors including socio-demograph-
ics, co-morbidities, co-medications and severity of illness. Results: Out of a total 
cohort of 299,462 patients, 200,552 patients were on either ACEIs or ARBs. 187,478 
patients were taking ACEIs and 25,987 were taking ARBs. There was no significant 
difference in reduction of risk of mortality with use of ARBs versus ACEIs (HR 0.955, 
95% CI: 0.907-1.006). Results from stratification using propensity score analysis also 
suggest the same. Patients were stratified into 5 groups based on propensity to 
receive ARB. Proportion of patients that died was not significantly different for ACEI 
and ARB in four out of the five groups. Among ACEIs, Enalapril (HR 0.715, 95% CI: 
0.584-0.876), Fosinopril (HR 0.778, 95% CI: 0.729-0.830) and Lisinopril (HR 0.784, 95% 
CI: 0.740-0.831) were significantly better than Captopril in reducing risk of mortal-
ity. Among ARBs, Candesartan (HR 0.847, 95% CI: 0.751-0.994) and Irbesartan (HR 
0.892, 95% CI: 0.795-1.00) were significantly better than Losartan in reducing risk 
of mortality. ConClusions: Results from the study suggest that ARBs are equally 
effective as ACEIs in reducing risk of mortality in heart failure patients and there 
are significant differences in effectiveness of individual drugs within ACEIs and 
ARBs in reducing risk of mortality in heart failure.
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objeCtives: To measure the effectiveness of adherence interventions for oral hypo-
glycemics, antihypertensives, and statins on medication adherence and acute hos-
pitalization (emergency room [ER] and inpatient) in three Medicaid managed care 
organizations (MCOs) in Southeastern Pennsylvania (SEPA) and Lehigh/Capital-New 
West Pennsylvania (LCNWPA). Methods: One-year follow-up analysis of prescrip-
tion and hospitalization member data with prescription fills for hypoglycemics, 
statins, and/or antihypertensives from January 1 to December 31, 2012. Thirty inter-
ventions— categorized as general interventions (GI) for all subjects and personalized 
interventions (PI) for higher-risk care-managed subjects—were implemented to 
improve 2013 adherence. Medication adherence (proportion of days covered [PDC]; 
baseline inclusion criterion: 20%–67%) and acute hospitalization rates (utilization 
per thousand members per year) were calculated at baseline and at one-year post-
intervention. Results: Of 6,382 participants (1,607 LCNWPA; 4,775 SEPA), 1,044 
were PI subjects (579 LCNWPA; 465 SEPA). SEPA and LCWPA member profiles were 
demographically similar to one another, except regarding race and ethnicity. The 
PDC rate improvements for all three medication classes were 13.14% for LCNWPA 
and 14.15% for SEPA (P< 0.01 for both), accompanied by significant increases in 
inpatient admissions (+11.0% and +1.9%, respectively; P< 0.01 for both); the SEPA 
cohort also experienced an increase in inpatient admissions—small in magnitude, 
but statistically significant (+0.3%; P< 0.01). Improvements in mean PDC were sig-
nificantly greater in PI than GI subjects (LCNWPA: 16.12% vs. 11.46%, P< 0.01; SEPA: 
20.95% vs. 13.42%, P< 0.01), but increases in acute hospitalization were also signifi-
cantly greater (P< 0.01 for all, except ER-[LCNWPA]) due to selection bias. Subjects 
demonstrating improvements in 2013 PDC rates displayed comparable changes in 
acute hospitalization rates as their non-improving counterparts. ConClusions: 
Multifaceted MCO-implemented adherence interventions significantly improved 
medication adherence in Medicaid participants, especially in higher-risk subjects. 
However, these PDC improvements were not necessarily translated into measurable 
reductions in acute hospitalization over the one-year post-intervention timeframe.
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objeCtives: Adults undergoing cardiac surgery (CS) frequently receive intrave-
nous (IV) crystalloids perioperatively for resuscitation and maintenance of adequate 
circulating volume. Use of balanced crystalloids has been associated with more 
favorable outcomes versus non-balanced crystalloids, however studies compar-
ing outcomes among CS patients receiving different types of balanced crystalloids 
are lacking. We conducted a retrospective analysis using a large de-identified US 
electronic health record database to investigate differences in major outcomes 
among patients receiving different types of balanced crystalloids (during and up to 
72 hours post-CS). Methods: Patients undergoing CS between January 2009 and 
June 2013 were included if they received ≥ 500mL balanced crystalloid within 1 day 
following surgery and survived ≥ 1 day. Patients with a length-of-stay > 30 days, 
undergoing multiple CS procedures, or receiving > 1L fluid on the day preceding 
surgery were excluded (restricting the cohort to those undergoing routine elec-
tive CS). Following univariate descriptions, propensity-score matching was carried 
out and outcomes were compared (adjusted for confounders). Models compared 
patients receiving Plasma-Lyte® or Normosol® (PL-N) versus Lactated Ringer’s (LR), 
as these solutions differ in their electrolyte composition. The primary outcome 
was 90-day in-hospital mortality (during index hospitalization or readmission). 
Additional outcomes included daily per-patient costs, renal, cardiac and vascular 
events, respiratory failure, and infectious, gastrointestinal, and neurologic compli-
cations. Results: 4,089 patients met inclusion criteria. We selected 299 patients 
receiving PL-N and matched them using propensity-score-based greedy matching 
methods with an equal number receiving LR. There were significant regional dif-
ferences in the choice of crystalloid (PL-N more common in the South). Odds of 
90-day mortality following the receipt of PL-N versus LR were 0.96 [0.94;0.97]. Daily 
per-patient costs and odds of respiratory failure were significantly lower among 
patients receiving PL-N. ConClusions: Receipt of PlasmaLyte® or Normosol® 
rather than LR perioperatively in CS patients may be associated with improved 
outcomes and lower costs.
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objeCtives: First, to examine how both the effectiveness of valsartan centric regi-
mens and the patients-related factors affect the control rates of the Systolic Blood 
Pressure (SBP), Diastolic (DBP) and combined SBP/DBP; specifically for Belgian patients 
with a history of failed or intolerant anti-hypertensive treatment. Secondly, to assess 
the effectiveness of valsartan treatment groups and the related factors concerning 
a patients’ total cardiovascular risk (TCVR) residuals. Lastly, to attempt to estimate 
the cost avoidance factor associated with taking varying levels of valsartan treat-
ment doses. Methods: This research took the form of a secondary-data analysis. 
The variants of valsartan doses given to patients included: valsartan monotherapy, 
a combination of valsartan with hydrochlorothiazide, and a combination of valsar-
tan with amlodipine. We applied Bailey’s approach, using Kaplan-Meier curves to 
estimate the distribution of treatment intensity at which the target rates of SBP, DBP 
and SBP/DBP were achieved. Results: A total of 17,683 patients were included in 
this study. Overall, there was a statistically significant increase in the proportion of 
patients with controlled SBP, DBP and combined SBP/DBP after 90 days of starting on 
valsartan-centric regimens (p< 0.001). Both older age and the presence of diabetes 
were associated with a lower control rate of SBP, DBP and combined SBP/DBP (P< 0.05). 
Substantial reductions in total cardiovascular risk, particularly in the very high added-
risk category was observed and an increase in the low added risk TCVR (p< 0.001). 
The associated cost avoidance with varying levels of treatment intensity were dose 
related. ConClusions: Valsartan-centric regimens were effective in increasing the 
control rates of SBP, DBP and combined SBP/DBP in the real practice for patients whose 
prior treatment failed. Not only did valsartan regimens improve the BP control rate, 
they also reduced the TCVR residuals. Additionally, substantial cost avoidance was 
found to be associated with the use of higher levels of treatment intensity.
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objeCtives: To compare early mortality after aortic valve replacement (AVR) 
between the recipients of mechanical and bioprosthetic aortic valves. Methods: 
A retrospective analysis of patients 65 years or older in the 2006-2011 Medicare 
databases who underwent AVR. In the mixed effects models adjusting for physi-
cian and hospital random effects, we estimated odds ratios (OR) of early mortality, 
comparing mechanical versus bioprosthetic valves. Early mortality was measured as 
death on the surgery date, death within 1-30 and 31-365 days after the surgery date, 
death within 30 days after the hospital discharge date and operative mortality (death 
within 30 days following surgery, or at discharge, whichever is longer). Results: 
Of the 66,453 Medicare beneficiaries included in the study, 19,190 (28.88%) received 
a mechanical valve and 47,263 (71.12%) received a bioprosthetic valve. The risk of 
death on the surgery date was 60% higher for mechanical valves than for biopros-
A134  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
PCV28
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objeCtives: Arterial hypertension (AH) largely determines the high mortality rate 
and disability of working age persons from coronary heart diseases. In Ukraine 
in 2012 according to official statistics 12.1 million patients with AH were regis-
tered. It is 32.2% of the adult population. The purpose of the study - assessment 
structure and volume of antihypertensive drugs (AHDs) consumption during 2008-
2013 in Ukraine. Methods: Analysis of AHDs consumption was performed using 
ATC/DDD-methodology and data of drugs supply in informational-search system 
“Pharmaceuticals” of company MORION during 2008-2013. Consumption of AHDs 
was determined in the indicator: DDDs / 1000 inhabitans / day (DIDs). AHDs of the 
first-line: thiazide and thiazide-type diuretics, β -blockers, calcium channel block-
ers, ACE inhibitors, angiotensin II receptor blockers and the second line: α -block-
ers, central antiadrenergic drugs, peripheral vasodilators were analyzed. Results: 
Volume of AHDs consumption increased from 60,64 DIDs in 2008 to 96,43 DIDs in 
2013. About 6.08% - 9.6% of inhabitans take one DDD per day. Recalculation vol-
umes of AHDs consumption for a total aggregate of patients with AH showed that 
only 23% - 36% of patients receive treatment. This testifies to the low adherence of 
patients to treatment. A comparison the volumes of AHDs consumption has shown 
that the consumption of AHDs in Ukraine is less, but stroke mortality is higher than 
in the developed countries. Consumption of AHDs of the first line accounts for a 
large share which increased from 83.7% in 2008 to 89.3% in 2013. Consumption of 
AHDs of the second line decreased. ConClusions: Structure of AHDs consump-
tion in Ukraine indicates compliance of antihypertensive therapy to current clinical 
guidelines. The consumption of AHDs in Ukraine is less than in other countries, 
so the most urgent problem for Ukraine is to find mechanisms for increasing the 
adherence of patients to hypertension treatment.
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objeCtives: To assess in a community setting how patients discharged alive after 
an ACS are treated with statins. Specifically, the rate of prescription, the dosages and 
1-year adherence have been evaluated. Methods: From the ARNO Observatory, we 
carried out a record linkage analysis of discharge records for ACS and prescription 
databases, which included 2,989,512 subjects of 7 Local Health Authorities from 
Northern to Southern Italy. The accrual period lasted from January 1 to December 
31, 2011. Results: Of the 2,989,512 subjects, 6,226 (2.1‰) were hospitalized for ACS 
over the 12 months of observation, 58% of patients were aged more than 70 years, 
females accounted for 36% of the cases, diabetes was reported in 31%. In-hospital 
all-cause death was 4.6%. Of the patients discharged alive, 69.9% received a statin 
treatment at the time of discharge. High dosage of statins were used in 70.4% of 
cases. After 1 year follow-up, adherence to treatment was observed in 71.7% of 
patients. Over the 1-year follow-up, 63.3% of the patients needed to be readmit-
ted again (50.4% for cardiovascular causes). The average yearly cost per patient for 
the total ACS population was 16,897€ /year (drugs, 1,692€ ; hospitalizations, 14,198€ ; 
diagnostic and outpatient visits, 1,007€ ). ConClusions: In a community setting, 
the rate of prescription of statins after an ACS seems to be at least suboptimal. 
However, the dosages of prescribed statins suggest that the use of intensive statin 
treatment increased over the last few years. Prescription continuity over time was 
not adequately followed. Patients with ACS have high direct healthcare costs, rehos-
pitalization being the main cost driver. There is still a gap between evidence based 
recommendations and what actually happens in the routine clinical practice, surely 
determining a high social and economical burden for the national health structures.
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Tiwari P.1, Sunarikani R.1, Malhotra S.2
1NIPER MOHALI INDIA, MOHALI, India, 2Private Hospital, MOHALI, India
objeCtives: Despite the availability of effective prophylactic and therapeutic 
options, VTE continues to be under diagnosed and undertreated. The incidence of 
DVT in India, however, is comparable to that in the Western countries. This study 
aimed to assess the adherence of treatment guidelines in the prophylaxis of DVT 
and evaluated the risk factors associated with DVT. Methods: The prospective 
study was carried out at an Indian tertiary healthcare setting where the patients 
were enrolled in the study as per the defined inclusion and exclusion criteria. The 
results are based on findings from a total of 230 patients. The patients were clas-
sified into four different categories based on the risk of DVT- low, moderate, high 
and highest. Results: The results are based on data obtained from 158 female 
and 72 male patients. The average age of the patients was found to be 62.1±0.9 
yrs. The average age of female patients was found to be statistically significantly 
higher than the average age of male patients. Of 230 patients, 207 patients received 
Enoxaparin/ Rivaroxaban/ Diateparin for prophylaxis and 5 patients through DVT 
pump and limb physiotherapy. It was found that 18 patients did not receive any type 
of DVT prophylaxis; and, out of 18 patients, 10 were managed for DVT prophylaxis 
with active toe movements. The adherence to the pharmacological prophylaxis 
was found to be 92.2%. ConClusions: The results of this study have shown that 
the adherence to ACCP guidelines in DVT prophylaxis in this study population was 
high (92.2%). Further, an association between surgery (major surgery, orthopaedical 
surgery), age and DVT risk appears to be existent.
objeCtives: Clinical trials comparing rivaroxaban or dabigatran to warfarin 
show similar results for major and non-major clinically relevant bleeding. Post-
marketing data regarding bleeding rates for these new oral anticoagulants (NOACs) 
is lacking. Our goal was to evaluate bleeding related outcomes with NOACs using 
a disproportionality analysis of spontaneous adverse event reports. Methods: 
We evaluated the FAERS database from 10/2011 – 12/2012 to compare frequency 
of events in reports of rivaroxaban, dabigatran, and warfarin related to fatal and 
non-fatal bleeding. Reports were included if the anticoagulant was the primary 
suspected agent for the event. Reporting odds ratio (ROR) and proportional report-
ing ratio (PRR) were calculated to estimate risk for each anticoagulant. Results: 
Of 22,244 eligible adverse drug reports for the anticoagulants, 7661 (34%) bleed-
ing reports were submitted, with 1868 (24%) deaths, 5028 (66%) hospitalizations 
and 1040 (14%) life-threatening events. Dabigatran was the most commonly 
reported anticoagulant exposure among bleeding cases (n= 5203, 68%). Of the 
bleeding cases associated with dabigatran, death was reported in 29%, hospi-
talization in 67%, and life-threatening events in 15% of cases. The odds of expo-
sure for fatal bleeding was significantly higher with dabigatran (ROR 2.28, 95% 
confidence interval [CI] 2.02-2.56) and significantly lower with rivaroxaban (ROR 
0.75, CI = 0.69-0.8) and warfarin (ROR 0.53, CI = 0.44-0.63). PRR indicated sig-
nificantly increased risk of non-fatal bleeding with dabigatran (PRR = 2.12, CI 
= 1.99-2.24) and warfarin (PRR = 1.27, CI = 1.17-1.38) with a significant decrease 
associated with rivaroxaban (PRR 0.8, CI = 0.75-0.86). ConClusions: Among the 
NOACs, patients having fatal and non-fatal bleeding were found to have higher 
odds of dabigatran exposure and significantly lower odds of rivaroxaban expo-
sure. Though FAERS is subject to significant bias, the results suggest dabigatran-
related bleeding is higher in clinical practice and rivaroxaban may be a safer 
alternative.
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objeCtives: Arterial hypertension represents a major cause of morbidity and 
mortality among elderly population in Novi Sad, Serbia. The aim of this study 
was to analyze patterns and address financial aspects of antihypertensive drug 
utilization among elderly outpatients (> 60). Methods: Data on antihypertensive 
issued on prescription were collected from all state-owned pharmacies in Novi Sad 
(population 350,000) from September 2011 to February 2012. Consumption was cal-
culated using the ATC/DDD methodology, and results were expressed in DDD/1000 
inhabitants/day. DU90% (drug utilization 90%) segment and price per DDD were 
determined. Results: The total use of antihypertensives among population > 60 
years in Novi Sad, Serbia was 203.1 DDD/1000inh/day. ACE inhibitors were the most 
frequently used drugs and accounted for 58.44% of total consumption, followed 
by calcium channel blockers (23.51%) and beta-blockers (11.10%). Consumption of 
diuretics (4.29%) and angiotensin receptor antagonists (< 3%) was low. High use of 
ACE inhibitors was also reflected in DU90% profile. Even though most commonly 
prescribed drug was amlodipine (18.49%), out of 16 drugs within DU90% segment, 
10 were ACE inhibitors or ACE inhibitors/diuretics fixed combinations. Average 
price per DDD within DU90% was 0.09 euro per DDD whereas it was 0.12 euro 
per DDD for drugs beyond the DU90% segment. ConClusions: High consump-
tion of ACE inhibitors and disregard to other antihypertensive agents points to 
therapeutic irrationalities which can have considerable clinical and economic 
consequences. Targeted education may both improve efficacy of treatment of 
hypertension in elderly and provide significant savings. Acknowledgement: This 
work was supported by the Ministry of Science and Technological Development, 
Republic of Serbia, project No. 41012.
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objeCtives: Anxiety and depression are prevalent in individuals with coronary 
heart disease. Selective-serotonin reuptake inhibitors (SSRI) are first-line therapy 
for many anxiety and depression disorders. Platelet aggregation inhibitors (PAI) 
are the cornerstone of therapy for various types of heart disease. These medi-
cations are relatively contraindicated due to an increased risk for many types 
of bleeding. The purpose of the study was to examine the prevalence and pre-
dictors of use of both SSRI and PAI among individuals with co-occurring heart 
disease and anxiety or depression. Methods: Respondents who were age 22 
years and older, alive throughout the study period, diagnosed with heart dis-
ease and co-occurring anxiety or depression (n= 1,253) in 2009-11 of the Medical 
Expenditures Panel Survey were included. Use of treatment was grouped as: 1) 
SSRI and PAI, 2) SSRI or PAI, and 3) Neither SSRI or PAI. Results: Overall, 11.2% 
used both SSRI and PAI, 46.3% used SSRI or PAI, and 42.5% used neither SSRI 
nor PAI. Significant subgroup differences were observed in the use of treat-
ment. Females were less likely to be prescribed the inappropriate combination 
[AOR 0.57 (95%CI= 0.36-0.92)] while respondents having education less than 
high school [AOR 2.27 (95%CI= 1.30-3.99)] or a diagnosis of diabetes [AOR 2.13 
(95%CI= 1.28-3.53)] were more likely to be prescribed the inappropriate combina-
tion. ConClusions: In this sample potentially inappropriate medication use 
was prevalent. Patients with less education or lower socioeconomic status are 
more likely to have health disparities and are at higher risk for both physical and 
mental health conditions. In this study, the patients with lower levels of education 
were more likely to be receiving an inappropriate combination of medications. 
The strong association with diabetes diagnosis and treatment choice is important 
because of the increased risk for bleeding in patients who received treatment for 
diabetes.
